Publications by authors named "Kelvin Yan"
Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma.
Expert Opin Investig Drugs
October 2024
Article Synopsis
- Nasopharyngeal carcinoma (NPC) is a prevalent disease in some regions, often diagnosed at an advanced stage, with traditional chemotherapy showing limited progress until recently.
- Recent advancements include investigational treatments like anti-vascular agents, signaling pathway inhibitors, and immunotherapies that are being explored for advanced NPC.
- The incorporation of immune-checkpoint inhibitors into standard chemotherapy has transformed first-line treatment options, with ongoing research into new combinations and maintenance therapies for improved outcomes in subsequent treatment lines.
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT preferentially improves EFS in comparison to NC followed by adjuvant trastuzumab initiated postoperatively (NCAT) has not been addressed.
View Article and Find Full Text PDFRole of fulvestrant in the management of postmenopausal breast cancer.
Expert Rev Anticancer Ther
November 2011
Fulvestrant is a form of endocrine therapy used in the treatment of postmenopausal breast cancer. It has a unique mechanism of action in that it causes the degradation of estrogen receptor and therefore has been labeled a selective estrogen receptor downregulator. Unlike the selective estrogen receptor modulator tamoxifen, it has no agonistic properties and is therefore a pure anti-estrogen.
View Article and Find Full Text PDF